We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PCR Assay Monitors CMV in Immunocompromised Patients

By HospiMedica staff writers
Posted on 12 Jul 2006
A quantitative real-time polymerase chain reaction (PCR) test provides rapid and accurate diagnosis of cytomegalovirus (CMV) and improved management of immunocompromised patients.

The Smart CMV assay was launched by Cepheid (Sunnyvale, CA, USA) for clinical diagnostic use on its SmartCycler system. More...
The assay has received the CE mark under the European Directive for in vitro diagnostic (IVD) medical devices. Intended for rapid detection and quantitation of CMV viral load, the assay monitors patients for infections that can be asymptomatic and lead to latent infection and reinfection. CMV, which is a herpes virus, is a significant cause of infection and mortality among immunocompromised patients, such as organ transplant recipients andAIDS and cancer patients.

Detection of active CMV infection plays a critical role in diagnosis and treatment. Periodic monitoring of CMV viral load in consecutive clinical samples is used to identify high-risk patients and to monitor their response to CMV therapy. Because of their specificity and sensitivity, real-time PCR diagnostics such as Smart CMV are an important tool in the effective clinical management of CMV patients.

Professor Mario Poljak, M.D., Ph.D., head of the Laboratory for Molecular Microbiology and the Slovenian AIDS Reference Center at the University of Ljubljana (Slovenia) said, "In transplant recipients, CMV load is used to diagnose active CMV disease, screen patients for the use of preemptive therapy, and monitor the response to antiviral therapy. In patients infected with human immunodeficiency virus type 1, the risk of developing CMV disease has been reported to be directly related to the quantity of CMV DNA in plasma.”

By automating the amplification and detection process, the SmartCycler system delivers accurate and consistent test results from prepared biologic samples in approximately 30-40 minutes. With up to 96 independently programmable reaction sites, the system can simultaneously run different tests with different protocols and at different times. This eliminates complex advanced scheduling on larger, more costly systems as well as the need to transport samples to central facilities for analysis.

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.



Related Links:
Cepheid

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.